Drug-coated balloon catheter with recyclable drugs

Abstract

This invention discloses a drug-coated balloon catheter with retrievable drugs, comprising a catheter and a balloon unit. The balloon unit includes first to fifth balloons. The first balloon is fitted at the distal end of the catheter to carry the drug. The second and third balloons are fitted at the proximal and distal ends of the first balloon, respectively. The fourth and fifth balloons are fitted at the proximal and distal ends of the second and third balloons, respectively. When the drug-coated balloon catheter is in the closed state, all five balloons are in a contracted state. When in the drug release state, the second and third balloons expand and adhere to the blood vessel wall to form a working area, so that the drug released by the expanded first balloon is blocked in the working area and will not be lost to other places with the blood flow. In the drug retrieval state, the first to third balloons are in a closed state, and the fourth and fifth balloons are in an expanded state to adhere to drugs, thrombi, or plaques floating in the blood vessel, ensuring the quality of vascular interventional treatment and reducing the risk of blockage.

Description

Technical Field

[0001] This invention relates to the field of medical device technology, and in particular to a drug-coated balloon catheter with recyclable drugs. Background Technology

[0002] Drug-coated balloon catheters are balloon catheters with a drug-coated surface on a standard bare balloon. After the drug-loaded balloon is delivered to the lesion site, the balloon inflates, restoring patency to the vessel wall. Simultaneously, the drug coating washes off from the balloon surface and is released into the vessel wall, further inhibiting smooth muscle cell proliferation and preventing restenosis. Therefore, drug-coated balloon catheters not only establish a blood supply channel through balloon inflatation but also avoid defects such as in-stent restenosis and thrombosis that often occur after stent implantation.

[0003] Existing drug-coated balloon catheters typically use a balloon catheter with a balloon section. A drug coating is applied to the outer surface of this balloon section, and the drug-loaded balloon is then delivered to the lesion site and inflated according to the characteristics of the lesion. However, during intravascular delivery, these drug-coated balloon catheters experience drug loss rates exceeding 50% due to high-speed blood flow, reducing the amount of drug that can be released at the lesion site and affecting device effectiveness. Furthermore, the drug washed away by the blood can detach and block distal blood vessels, increasing the body's metabolic burden and reducing device safety.

[0004] Therefore, it is necessary to provide a drug-coated balloon catheter that can reduce drug loss in the bloodstream and enable the recovery of drug particles floating in the blood to solve the above problems. Summary of the Invention

[0005] The purpose of this invention is to provide a drug-coated balloon catheter that can reduce drug loss in the bloodstream and allow drug particles floating in the blood to be recovered.

[0006] To achieve the above objectives, the technical solution of the present invention is as follows: A drug-coated balloon catheter with retrievable drugs is provided, comprising a catheter and a balloon unit; wherein the catheter has a first cavity, a second cavity, a third cavity, and a fourth cavity that are isolated from each other, the first cavity being located at the center of the catheter to form a guidewire cavity; the balloon unit includes a first balloon, a second balloon, a third balloon, a fourth balloon, and a fifth balloon, the first balloon being sleeved on the distal end of the catheter and communicating with the second cavity, the second balloon and the third balloon being sleeved on the proximal and distal ends of the first balloon, respectively, and both communicating with the third cavity, the fourth balloon and the fifth balloon... The first balloon is respectively fitted onto the proximal and distal ends of the second and third balloons, and both are connected to the fourth cavity; wherein, the first balloon is used to carry the drug; the drug-coated balloon catheter has a closed state, a drug release state, and a drug recovery state; in the closed state, the first to fifth balloons are in a contracted state; in the drug release state, the first to third balloons are in an expanded state, and the fourth and fifth balloons are in a contracted state; in the drug recovery state, the first to third balloons are in a closed state, and the fourth and fifth balloons are in an expanded state.

[0007] Preferably, the surface of the first balloon is provided with a plurality of grooves, the grooves being filled with liposomes containing drugs. The use of liposomes can increase drug loading efficiency and improve drug stability, thereby reducing the impact of blood flushing on the drug during delivery, effectively preventing drug detachment and reducing drug loss.

[0008] Preferably, the groove is covered with a covering film, and the covering film has a cutting line. The cutting line breaks when squeezed or stretched, so that the drug in the groove is released from the first balloon. The covering film can protect the drug from falling out during the passage of blood vessels, and the cutting line on the covering film will break when subjected to force, so that the drug can be released and the covering film will not fall into the blood.

[0009] Preferably, when the first balloon is in a contracted state, the drug on its surface is encapsulated, which can effectively prevent the blood from washing away the drug and reduce drug loss during delivery; when the first balloon is in an inflated state, the drug on its surface is exposed and can contact blood vessels.

[0010] Preferably, the surfaces of the fourth balloon and the fifth balloon are provided with an oleophilic coating, which is used to adhere thrombi and drugs, reducing the risk of blockage by drugs, thrombi, etc.

[0011] Preferably, when the fourth and fifth balloons are in the expanded state, their cross-sections are arc-shaped, and the bowstrings of the fourth and fifth balloons face the first balloon, while the backs of the bows of both are far away from the first balloon.

[0012] Preferably, the bowstring surfaces of the fourth and fifth balloons are provided with supporting ribs. When the fourth and fifth balloons are in a contracted state, the supporting ribs are folded. When the fourth and fifth balloons are in an expanded state, the supporting ribs are unfolded and radial. The supporting ribs enable the expanded fourth and fifth balloons to have a certain strength, hardness and maintain their set shape.

[0013] Preferably, the outer diameter of the fourth and fifth balloons in the expanded state is smaller than the outer diameter of the second and third balloons in the expanded state, so that the outer diameter of the fourth and fifth balloons does not come into close contact with the blood vessel wall. Therefore, the fourth and fifth balloons can adhere to drugs and plaques floating in the blood.

[0014] Preferably, the drug-coated balloon catheter with retrievable drug further includes several metal rings disposed on the catheter and located inside the first balloon. The metal rings are used to reflect the ultrasonic waves emitted by the external ultrasound probe. The ultrasonic waves can promote the accelerated release of the drug and cause the thrombus on the inner wall of the blood vessel to break into small pieces and fall into the blood vessel under the cavitation effect of the ultrasonic waves.

[0015] Preferably, the metal ring is provided with a plurality of micropores, which cause the ultrasonic waves to be reflected multiple times to amplify the cavitation effect of the ultrasonic waves.

[0016] Preferably, the drug-coated balloon catheter with retrievable drug further includes a tip and a needle hub; wherein the tip is connected to the distal end of the catheter and communicates with the first cavity; the needle hub is connected to the proximal end of the catheter and has a first interface, a second interface, a third interface, and a fourth interface, the first interface communicating with the first cavity, the second interface communicating with the second cavity for inflating and deflating the first balloon, the third interface communicating with the third cavity for inflating and deflating the second and third balloons, and the fourth interface communicating with the fourth cavity for inflating and deflating the fourth and fifth balloons.

[0017] Preferably, the tip is a tapered head, and the distal diameter of the tip is smaller than its proximal diameter, so that the tip can avoid vascular damage when the drug-coated balloon catheter is advanced along the guidewire.

[0018] Compared with the prior art, the drug-coated balloon catheter of the present invention, which allows for the recovery of drugs, firstly places a second balloon and a third balloon at the proximal and distal ends of the first balloon, respectively. Therefore, when the drug-coated balloon catheter is in the drug release state, all three balloons are inflated, allowing the ends of the second and third balloons to adhere tightly to the blood vessel wall. A working zone is formed between the second and third balloons, and the drug released on the first balloon is blocked in the working zone, preventing it from being lost to other places with the blood flow and avoiding the problem of drug leakage from both sides into other areas of the blood vessel. Secondly, in the drug release process... When the drug-coated balloon catheter is in the drug recovery state, the fourth and fifth balloons dilate to adhere to floating drugs, thrombi, or plaques in the blood vessel, thereby promptly clearing away these substances and ensuring the quality of interventional vascular treatment while reducing the risk of drug blockage. Furthermore, the first balloon carries the drug; when the drug-coated balloon catheter is in the retracted state, all five balloons are in a contracted state. This ensures that the drug is contained within the balloons as the catheter moves within the blood vessel, reducing drug loss and increasing the amount of drug that can be released at the lesion site, thus improving the effectiveness of the device. Attached Figure Description

[0019] Figure 1 This is a cross-sectional view of the drug-coated balloon catheter of the present invention in the drug release state.

[0020] Figure 2 yes Figure 1 A schematic diagram showing the interaction between the drug-coated balloon catheter and the external ultrasound probe.

[0021] Figure 3 This is a cross-sectional view of the drug-coated balloon catheter of the present invention in the drug recovery state.

[0022] Figure 4 It is along Figure 3 A cross-sectional view along line AA in the middle.

[0023] Figure 5 yes Figure 1 Top view of the first balloon in the middle.

[0024] Figure 6 This is a schematic diagram of the structure of the covering film in this invention.

[0025] Figure 7 yes Figure 5 A schematic diagram of the folded state of the first balloon.

[0026] Figure 8 yes Figure 5 A schematic diagram of another folded state of the first balloon.

[0027] Figure 9 yes Figure 3 Side view of the fifth balloon. Detailed Implementation

[0028] Embodiments of the present invention will now be described with reference to the accompanying drawings, in which similar element reference numerals represent similar elements. It should be noted that the directional descriptions involved in the present invention, such as up, down, left, right, front, and rear, indicating directions or positional relationships, are based on the directions or positional relationships shown in the drawings and are only for the convenience of describing the technical solutions of this application or / and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation, and therefore should not be construed as a limitation of this application. The terms "first," "second," etc., described are only used to distinguish technical features and should not be construed as indicating or implying relative importance, or implicitly indicating the number of indicated technical features, or implicitly indicating the sequential relationship of the indicated technical features.

[0029] Combination Figures 1-9 As shown, the drug-coated balloon catheter 1 for recyclable drugs provided by the present invention includes a needle hub 100, a catheter 200, a balloon unit 300, and a tip 400. The needle hub 100 is connected to the proximal end of the catheter 200, the tip 400 is connected to the distal end of the catheter 200, and the balloon unit 300 is sleeved on the distal end of the catheter 200 and positioned near the tip 400.

[0030] First combine Figures 1-4 As shown, the catheter 200 has a first cavity 210, a second cavity 220, a third cavity 230, and a fourth cavity 240 that are isolated from each other. The first cavity 210 is located at the center of the catheter 200 and forms a guidewire cavity. See details below. Figure 4 As shown. The needle holder 100 has a first interface 110, a second interface (not shown), a third interface 130, and a fourth interface 140. The first interface 110 is located in the middle of the needle holder 100 and communicates with the first cavity 210. The second interface communicates with the second cavity 220. The third interface 130 communicates with the third cavity 230. The fourth interface 140 communicates with the fourth cavity 240. See details... Figures 1-3 As shown. The tip 400 is connected to the first cavity 210 of the catheter 200. That is, the first interface 110 of the needle hub 100, the first cavity 210 of the catheter 200 and the tip 400 are connected in sequence, and the guidewire is delivered through the first interface 110, the first cavity 210 and the tip 400.

[0031] Combination Figures 1-3As shown, the tip 400 in this invention is preferably a conical tip, and the distal diameter of the tip 400 is smaller than its proximal diameter. Therefore, when the drug-coated balloon catheter 1 is advanced along the guidewire, the tip 400 can avoid vascular damage. Of course, the tip 400 is not limited to a conical tip; it can be designed in any other shape that does not damage blood vessels.

[0032] The following will continue to combine Figures 1-4 As shown, in this invention, the balloon unit 300 includes a first balloon 310, a second balloon 320, a third balloon 330, a fourth balloon 340, and a fifth balloon 350. The first balloon 310 is fitted onto the distal end of the catheter 200 and connects to the second cavity 220. The first balloon 310 carries medication, and pressure is inflated and deflated through the second interface and the second cavity 220, causing the first balloon 310 to contract or expand. The second balloon 320 and the third balloon 330 are respectively fitted onto both sides of the first balloon 310. Specifically, the second balloon 320 is fitted onto the proximal end of the first balloon 310, and the third balloon 330 is fitted onto the distal end of the first balloon 310. The second balloon 320 and the third balloon 330 connect to the third cavity 230 through a first through-hole 231 formed on the catheter 200. (See attached diagram). Figures 1-3 As shown, therefore, the second balloon 320 and the third balloon 330 are pressurized and depressurized through the third interface 130 and the third cavity 230 to cause the second balloon 320 and the third balloon 330 to contract or expand. The fourth balloon 340 and the fifth balloon 350 are respectively fitted on both sides of the second balloon 320 and the third balloon 330. Specifically, the fourth balloon 340 is fitted on the proximal end of the second balloon 320, and the fifth balloon 350 is fitted on the distal end of the third balloon 330. The fourth balloon 340 and the fifth balloon 350 are connected to the fourth cavity 240 through the second through hole 241 opened on the catheter 200. See reference. Figures 1-3 As shown, pressure is supplied to the fourth balloon 340 and the fifth balloon 350 through the fourth interface 140 and the fourth cavity 240, causing them to contract or expand.

[0033] Continue to combine Figures 1-3 As shown, the drug-coated balloon catheter 1 of the present invention has a closed state, a drug release state, and a drug recovery state. When the drug-coated balloon catheter 1 is in the closed state, the first to fifth balloons 310-350 are all in a contracted state. At this time, the drug carried on the first balloon 310 is encapsulated inside. Therefore, during the movement of the drug-coated balloon catheter 1 along the guidewire, it can effectively prevent the high-speed flowing blood from washing away the drug and reduce drug loss. When the drug-coated balloon catheter 1 is in the drug release state, the first to third balloons 310-330 are in an expanded state, while the fourth balloon 340 and the fifth balloon 350 are in a contracted state. (See reference...) Figures 1-2As shown, at this time, a working zone is formed between the second balloon 320 and the third balloon 330. The drug released from the first balloon 310 is blocked in this working zone and will not be lost to other places with the blood flow. At the same time, the ends of the second balloon 320 and the third balloon 330 are tightly attached to the blood vessel wall 2, preventing drug leakage from both sides and thus preventing drug loss to other areas within the blood vessel. See Figure 3 As shown, when the drug-coated balloon catheter 1 is in the drug recovery state, the first to third balloons 310-330 all return to the contracted state, while the fourth balloon 340 and the fifth balloon 350 are in the expanded state. At this time, the fourth balloon 340 and the fifth balloon 350 can adhere to floating drugs, thrombi, or plaques during the lesion treatment process, and promptly remove floating drugs, thrombi, or plaques, ensuring the quality of vascular interventional treatment and reducing the risk of blockage by drugs, thrombi, plaques, etc.

[0034] See below. Figure 5 As shown, in this invention, the surface of the first balloon 310 is provided with a plurality of grooves 311, and the grooves 311 are filled with liposomes 312, which contain drugs. Liposomes 312 have the characteristics of high loading capacity, high biocompatibility, and high targeting efficiency. Using liposomes 312 can increase drug loading efficiency, and liposomes 312 can also improve drug stability, thereby reducing the impact of blood flushing on the drug during delivery, effectively preventing drug detachment, and reducing drug loss.

[0035] In this invention, the liposome 312 may be at least one of cholesterol, lecithin, soybean lecithin, cephalin, polyvinyl alcohol, and polylactic-co-glycolic acid copolymer. Of course, the materials are not limited to those mentioned above.

[0036] The following is combined with Figures 5-6 As shown, in a preferred embodiment of the present invention, a covering film 313 covers the groove 311. This covering film 313 can either cover only the groove 311 or completely wrap around the surface of the first balloon 310, thereby achieving the purpose of covering the groove 311. Furthermore, the covering film 313 has a cutting line 313a, which breaks when compressed or stretched, allowing the drug within the groove 311 to detach from the first balloon 310. The covering film 313 protects the drug from falling out during blood flow, thus reducing drug loss during delivery. The cutting line 313a on the covering film 313 breaks under pressure, allowing the drug to be released, and the covering film 313 itself does not fall into the bloodstream, ensuring the safety of the treatment.

[0037] The following is combined with Figures 1-2 , Figure 5 , Figures 7-8As shown, when the drug-coated balloon catheter 1 is in the retracted state, the first balloon 310 contracts so that the drug on its surface is coated. Therefore, during delivery, the blood can effectively prevent the drug from being washed away and reduce drug loss. When the first balloon 310 is in the inflated state, the drug on its surface is exposed and can contact the blood vessel.

[0038] See Figure 7 As shown, in one embodiment of the present invention, after the first balloon 310 is contracted, it is stacked into an inner layer and an outer layer spaced apart, and the inner and outer layers are staggered. More specifically, the outer layer forms three spaced outer balloon portions 310a, which are spaced apart radially along the first balloon 310; correspondingly, the inner layer forms three spaced inner balloon portions 310b, which are also spaced apart radially along the first balloon 310, and the three inner balloon portions 310b correspond to the gaps between the three outer balloon portions 310a. The outer balloon portions 310a and the inner balloon portions 310b are connected by a fold portion 310c.

[0039] See below. Figure 8 As shown, in another embodiment of the present invention, the first balloon 310, after contraction, is generally vortex-shaped. Specifically, after contraction, the first balloon 310 folds into three curved balloon flaps 310d, which are curved in the same direction. Figure 8 The three balloon segments 310d shown are all arranged in a clockwise direction, with the three segments spaced apart sequentially.

[0040] Understandably, the shape of the first balloon 310 after contraction is not limited to... Figures 7-8 The shape shown can, of course, be folded into any other shape.

[0041] Let's review below. Figure 3 As shown, in this invention, the surfaces of the fourth balloon 340 and the fifth balloon 350 are provided with an oleophilic coating. When both are inflated, the oleophilic coating is used to adhere to thrombi and drugs, reducing the risk of blockage by drugs, thrombi, etc.

[0042] Continue reading Figure 3 As shown, when the fourth balloon 340 and the fifth balloon 350 are in the expanded state, their cross-sections are approximately arc-shaped, and the fourth balloon 340 and the fifth balloon 350 are symmetrically located at the proximal and distal ends of the first balloon 310.

[0043] More specifically, the arch back 341 of the fourth balloon 340 is located on the side away from the first balloon 310, and the bowstring surface 342 of the fourth balloon 340 is located on the side facing the first balloon 310. Overall, the arch back 341 of the fourth balloon 340 is roughly spherical or curved and protrudes in the direction away from the first balloon 310. The bowstring surface 342 of the fourth balloon 340 is also not planar. It is also a curved surface that protrudes slightly in the direction away from the first balloon 310. However, the curvature of the arch back 341 and the bowstring surface 342 protruding in the direction away from the first balloon 310 is different.

[0044] Furthermore, one end of the bow back surface 341 and the bowstring surface 342 are respectively connected to the proximal and distal ends of the second through hole 241 on the conduit 200. Therefore, the connection positions of the bow back surface 341, the bowstring surface 342 and the conduit 200 are spaced apart, so that the fourth cavity 240 of the conduit 200 is connected to the fourth balloon 340. When the fourth balloon 340 is in the inflated state, the end of the bow back surface 341 and the bowstring surface 342 away from the conduit 200 forms a tip 343, and the bow back surface 341 and the bowstring surface 342 gradually converge towards the tip 343, thereby gradually reducing the distance between them. Figure 3 As shown.

[0045] Continue reading Figure 3 As shown, correspondingly, the arched back surface 351 of the fifth balloon 350 is also located on the side away from the first balloon 310, and the bowstring surface 352 of the fifth balloon 350 is located on the side facing the first balloon 310. Overall, the arched back surface 351 of the fifth balloon 350 is roughly spherical or curved, protruding away from the first balloon 310. The bowstring surface 352 of the fifth balloon 350 protrudes slightly away from the first balloon 310, forming a curved structure, but the curvature of the arched back surface 351 and the bowstring surface 352 protruding away from the first balloon 310 is different. Simultaneously, one end of the arched back surface 351 and the bowstring surface 352 are respectively connected to the proximal and distal ends of another second through-hole 241 on the catheter 200, connecting the fifth balloon 350 to the fourth cavity 240 of the catheter 200. Furthermore, the connection positions of the arched back surface 341 and the bowstring surface 342 of the fifth balloon 350 to the catheter 200 are spaced apart. When the fifth balloon 350 is in the inflated state, the end of its arched back 351 and bowstring surface 352 furthest from the conduit 200 forms a tip 353, and the arched back 341 and bowstring surface 342 gradually converge toward the tip 353, thereby gradually reducing the distance between them. Figure 3 As shown.

[0046] Combination Figure 3 , Figure 9As shown, more preferably, the surfaces of the fourth balloon 340 and the fifth balloon 350 are further provided with supporting ribs 360, which are radially arranged. The supporting ribs 360 enable the fourth balloon 340 and the fifth balloon 350 to have a certain strength, hardness and maintain their set shape.

[0047] Continue to combine Figure 3 , Figure 9 As shown, where Figure 9 This is a side view of the fifth balloon 350. Support ribs 360 are located on the bowstring surface 352 of the fifth balloon 350, with one end connected to the conduit 200 and the other end connected to the tip 353 of the fifth balloon 350 or near the tip 353. Multiple support ribs 360 are arranged radially. The support ribs 360 can fold as the fifth balloon 350 contracts and open as the fifth balloon 350 expands. When the fifth balloon 350 expands, the support ribs 360 open, supporting the fifth balloon 350 to maintain its shape and enhance its strength and rigidity.

[0048] The supporting ribs 360 on the fourth balloon 340 are configured in the same way as those on the fifth balloon 350, so they will not be described again.

[0049] Combined again Figures 1-3 As shown, the outer diameters of the fourth balloon 340 and the fifth balloon 350 in their expanded states are smaller than the outer diameters of the second balloon 320 and the third balloon 330 in their expanded states, ensuring that the outer diameters of the fourth balloon 340 and the fifth balloon 350 do not contact the vessel wall 2 (see Figure 2). Figure 3 Therefore, the fourth balloon 340 and the fifth balloon 350 can adhere to drugs, thrombi, plaques, etc. floating in the blood.

[0050] Continue reading Figures 1-3 As shown, the drug-coated balloon catheter 1 with recoverable drug also includes several metal rings 500. The metal rings 500 are disposed on the catheter 200 and located inside the first balloon 310. The metal rings 500 are used in conjunction with an external ultrasound device. Specifically, the ultrasound waves emitted by the external ultrasound probe of the external ultrasound device can be reflected by the metal rings 500. The ultrasound waves can promote the accelerated release of the drug, and the thrombus on the inner wall of the blood vessel will break into small pieces and fall into the blood vessel under the cavitation effect of the ultrasound waves.

[0051] More preferably, the metal ring 500 is provided with a plurality of micropores, which cause the ultrasonic waves to be reflected multiple times to amplify the cavitation effect of the ultrasonic waves.

[0052] Let's combine them again below. Figures 1-9The working principle and process of the drug-coated balloon catheter 1 with recyclable drugs of the present invention are explained as shown.

[0053] The first step is to establish a pathway. Specifically, after a successful percutaneous puncture, the guidewire is pushed to the target area of ​​the blood vessel, and then the drug-coated balloon catheter 1 of this invention is delivered to the target area along the guidewire. During the delivery process, the first to fifth balloons 310-350 are all in a retracted state. Therefore, the drug on the first balloon 310 is encapsulated, which can effectively prevent the high-speed flowing blood from washing away the drug, thereby reducing drug loss.

[0054] Upon reaching the target area, pressure is injected into the third cavity 230 through the third interface 130, thereby inflating the second balloon 320 and the third balloon 330. This causes the outer diameters of the second balloon 320 and the third balloon 330 to fit tightly against the vessel wall 2, forming a working area between the second balloon 320 and the third balloon 330. At this time, the target area is within the working area. (See reference...) Figure 1 As shown.

[0055] The second step is drug release. Pressure is injected into the second cavity 220 through the second interface, thereby inflating the first balloon 310. After inflation, the outer surface of the first balloon 310 adheres tightly to the blood vessel wall 2. At this point, the covering membrane 313 on the surface of the first balloon 310 ruptures under pressure, releasing the liposomes 312 and the drug, which then contact the blood vessel wall 2. See details... Figure 2 As shown.

[0056] Furthermore, when the external ultrasound device is working, the ultrasound waves generated by its external ultrasound probe 600 reach the metal ring 500, and the ultrasound waves reflected by the metal ring 500 act on the blood vessel wall 2, such as... Figure 2 As shown, the thrombus breaks into small pieces due to the cavitation effect of ultrasound and falls into the blood vessel. Furthermore, ultrasound can promote drug release, causing the drug to adhere to the blood vessel wall 2. The external ultrasound device is kept running for a certain period of time to ensure that the drug is fully released into the blood vessel wall 2.

[0057] The third step is drug recovery and withdrawal. Specifically, the fourth cavity 240 is pressurized through the fourth interface 140 to inflate the fourth balloon 340 and the fifth balloon 350. After the fourth balloon 340 and the fifth balloon 350 have inflated, their outer surfaces do not contact the blood vessel wall 2. Figure 3 As shown. Then, pressure is released through the second and third interfaces 130, causing the first to third balloons 310-330 to contract, as shown. Figure 3 As shown. Next, the catheter 200 is moved back and forth so that the fourth balloon 340 and the fifth balloon 350 adhere to drugs, thrombi, and plaques floating in the blood, so as to remove drugs, thrombi, and plaques in a timely manner.

[0058] After a period of time, the pressure is released at the fourth port 140, causing the fourth balloon 340 and the fifth balloon 350 to contract. Then, along the guidewire, the drug-coated balloon catheter 1 is withdrawn from the body. Local pressure is applied to stop the bleeding, or a suture is used to suture the hemostasis, thus completing the interventional treatment.

[0059] In summary, because the drug-coated balloon catheter 1 of the present invention has a second balloon 320 and a third balloon 330 respectively disposed at the proximal and distal ends of the first balloon 310, when the drug-coated balloon catheter 1 is in the drug release state, the first to third balloons 310-330 are all in an expanded state, so that the ends of the second balloon 320 and the third balloon 330 are closely attached to the blood vessel wall 2, and a working area is formed between the second balloon 320 and the third balloon 330. The drug released on the first balloon 310 is blocked in the working area and will not be lost to other places with the blood flow, and there will be no problem of drug leakage from both sides causing the drug to be lost to other areas in the blood vessel. Secondly, when the drug-coated balloon catheter 1 is in the drug recovery state, the fourth balloon 340 and the fifth balloon 350 expand to adhere to floating drugs, thrombi, or plaques in the blood vessel, thereby promptly clearing away these floating substances and ensuring the quality of vascular interventional therapy while reducing the risks of drug-induced blockage. Furthermore, the first balloon 310 carries the drug. When the drug-coated balloon catheter 1 is in the closed state, the first to fifth balloons 310-350 are all in a contracted state, ensuring that the drug is contained within the balloon during the movement of the drug-coated balloon catheter 1 within the blood vessel, reducing drug loss and increasing the amount of drug that can be released at the lesion site, thus improving the effectiveness of the device.

[0060] The above-disclosed embodiments are merely preferred embodiments of the present invention and should not be construed as limiting the scope of the present invention. Therefore, any equivalent variations made in accordance with the claims of the present invention are still within the scope of the present invention.

Claims

1. A drug-coated balloon catheter with recyclable drugs, characterized in that, include: The catheter has a first cavity, a second cavity, a third cavity and a fourth cavity that are isolated from each other, and the first cavity is located at the center of the catheter to form a guidewire cavity; The balloon unit includes a first balloon, a second balloon, a third balloon, a fourth balloon, and a fifth balloon. The first balloon is fitted over the distal end of the catheter and communicates with the second cavity. The second balloon and the third balloon are fitted over the proximal and distal ends of the first balloon, respectively, and both communicate with the third cavity. The fourth balloon and the fifth balloon are fitted over the proximal and distal ends of the second balloon and the third balloon, respectively, and both communicate with the fourth cavity. The first balloon is used to carry medication. The drug-coated balloon catheter has a closed state, a drug release state, and a drug recovery state; in the closed state, the first to the fifth balloons are all in a contracted state; in the drug release state, the first to the third balloons are in an expanded state, and the fourth and fifth balloons are in a contracted state; in the drug recovery state, the first to the third balloons are in a closed state, and the fourth and fifth balloons are in an expanded state. The surfaces of the fourth and fifth balloons are coated with an oleophilic coating, and the outer diameters of the fourth and fifth balloons in the expanded state are smaller than the outer diameters of the second and third balloons in the expanded state.

2. The drug-coated balloon catheter with recyclable drug as described in claim 1, characterized in that, The surface of the first balloon is provided with several grooves, and the grooves are filled with liposomes containing drugs.

3. The drug-coated balloon catheter with recyclable drug as described in claim 2, characterized in that, The groove is covered with a covering film, and the covering film has a cutting line. The cutting line breaks when squeezed or stretched, so that the drug in the groove is released from the first balloon.

4. The drug-coated balloon catheter with recyclable drug as described in claim 2 or 3, characterized in that, When the first balloon is in a contracted state, the drug on its surface is encapsulated; when the first balloon is in an inflated state, the drug on its surface is exposed and can contact blood vessels.

5. The drug-coated balloon catheter with recyclable drug as described in claim 1, characterized in that, The oleophilic coating is used to adhere thrombi and drugs.

6. The drug-coated balloon catheter with recyclable drug as described in claim 1 or 5, characterized in that, When the fourth and fifth balloons are in the expanded state, their cross-sections are arc-shaped, and the bowstring surfaces of the fourth and fifth balloons face the first balloon, while the back surfaces of the bows are far away from the first balloon.

7. The drug-coated balloon catheter with recyclable drug as described in claim 6, characterized in that, The bowstring surfaces of the fourth and fifth balloons are provided with supporting ribs. When the fourth and fifth balloons are in a contracted state, the supporting ribs are folded. When the fourth and fifth balloons are in an expanded state, the supporting ribs are unfolded and radiate outwards.

8. The drug-coated balloon catheter with retrievable drug as described in any one of claims 1-3, characterized in that, It also includes several metal rings, which are disposed on the catheter and located inside the first balloon. The metal rings are used to reflect the ultrasonic waves emitted by the external ultrasound probe, so that the thrombus on the inner wall of the blood vessel is broken into small pieces by the cavitation effect of the ultrasonic waves and falls into the blood vessel.

9. The drug-coated balloon catheter with recyclable drug as described in claim 8, characterized in that, The metal ring has several micro-holes, which cause the ultrasonic waves to be reflected multiple times to amplify the cavitation effect of the ultrasonic waves.

10. The drug-coated balloon catheter with retrievable drug as described in any one of claims 1-3, characterized in that, Also includes: The tip is connected to the distal end of the catheter and communicates with the first cavity; The needle hub is connected to the proximal end of the catheter and has a first interface, a second interface, a third interface, and a fourth interface. The first interface is connected to the first cavity, the second interface is connected to the second cavity, and is used to inflate and deflate the first balloon. The third interface is connected to the third cavity and is used to inflate and deflate the second balloon and the third balloon. The fourth interface is connected to the fourth cavity and is used to inflate and deflate the fourth balloon and the fifth balloon.

11. The drug-coated balloon catheter with recyclable drug as described in claim 10, characterized in that, The tip is a conical head, and the distal diameter of the tip is smaller than its proximal diameter.

Images